Nucleotide and amino acid sequences of asporins
AssigneeThe Texas A&M University System
InventorsStephen P. Henry, A.O. Magnus Hook, Richard Mayne
Life of this patent
Estimating the term…
Abstract
Mouse asporin protein and nucleic acid sequences are disclosed. The protein contains a unique aspartic acid region near the N-terminus. The central domain contains ten leucine rich repeats. Sequences consistent with other class I small leucine rich repeat proteoglycans (SLRP) are also observed. Methods of use for the protein include regulating the complement system, inhibiting fibrosis formation, regulating the growth of endothelial cells and angiogenesis, regulating or inhibiting the growth of cancer cells, and regulating the functions of neuromuscular junctions.
Claims19
An isolated protein comprising an amino acid sequence selected from the group consisting of:
- an amino acid sequence at least about 90% identical to SEQ ID NO:6;
- and
- an amino acid sequence immunoreactive with an antibody prepared using SEQ ID NO:6 as an antigen, the antibody being immunoreactive with SEQ ID NO:6.
An isolated protein comprising an amino acid sequence selected from the group consisting of:
- an amino acid sequence at least about 90% identical to SEQ ID NO:22;
- and
- an amino acid sequence immunoreactive with an antibody prepared using SEQ ID NO:22 as an antigen, the antibody being immunoreactive with SEQ ID NO:22.
An isolated nucleic acid molecule segment comprising a structural nucleic acid sequence encoding SEQ ID NO:6 or SEQ ID NO:22.
An isolated nucleic acid molecule segment comprising a structural nucleic acid sequence selected from the group consisting of:
- a nucleic acid sequence at least about 90% identical to SEQ ID NO:2;
- and
- a nucleic acid sequence that hybridizes under stringent hybridization conditions to the reverse complement of SEQ ID NO:2.
A recombinant vector comprising operatively linked in the 5′ to 3′ orientation:
- a promoter that directs transcription of a structural nucleic acid sequence;
- a structural nucleic acid sequence selected from the group consisting of:
- a nucleic acid sequence at least about 90% identical to SEQ ID NO:2;
- and
- a nucleic acid sequence that hybridizes under stringent hybridization conditions to the reverse complement of SEQ ID NO:2;
- and
- a 3′ transcription terminator.
A recombinant host cell comprising a structural nucleic acid sequence selected from the group consisting of:
- a nucleic acid sequence at least about 90% identical to SEQ ID NO:2;
- and
- a nucleic acid sequence that hybridizes under stringent hybridization conditions to the reverse complement of SEQ ID NO:2;
- wherein the copy number of the structural nucleic acid sequence in the recombinant host cell is higher than the copy number of the structural nucleic acid sequence in a wild type host cell of the same species.
An antibody prepared using SEQ ID NO:6 or SEQ ID NO:22 as an antigen, wherein the antibody is immunoreactive with SEQ ID NO:6 or SEQ ID NO:22.
A method of preparing a recombinant host cell, the method comprising:
- selecting a host cell;
- transforming the host cell with a recombinant vector;
- and
- obtaining recombinant host cells;
- wherein the recombinant vector comprises a structural nucleic acid sequence selected from the group consisting of:
- a nucleic acid sequence at least about 90% identical to SEQ ID NO:2;
- and
- a nucleic acid sequence that hybridizes under stringent hybridization conditions to the reverse complement of SEQ ID NO:2.
A method for regulating the complement system of an organism, the method comprising administering an effective amount of asporin to the organism.
A method for inhibiting fibrosis formation in an organism, the method comprising administering an effective amount of asporin to the organism.
A method for regulating the growth of endothelial cells and angiogenesis, the method comprising administering an effective amount of asporin to the endothelial cells.
A method for inhibiting the growth of cancer cells, the method comprising administering an effective amount of asporin to the cancer cells.
A method of regulating the functions of neuromuscular junctions, the method comprising administering an effective amount of asporin to the neuromuscular junctions.
Dependencies are inferred from the claim text.